Article Text

PDF
AB0283 Dermatologic adverse events in a cohort of patients with rheumatoid arthritis using anti-tnf therapy in a real-life setting
  1. A. P. Real1,1,
  2. A. Palomino1,
  3. L. Villarreal1,
  4. J. Bello1,
  5. P. Santos-Moreno1
  1. 1Rheumatology, Biomab, Center For Rheumatoid Arthritis, Bogota, Bogota, Colombia

Abstract

Background Biological therapy is a major therapeutic tool to prevent clinical and radiological progression of rheumatoid arthritis (RA). On the other hand, adverse effects of these medications are a problem in clinical practice.

Objectives The aim of this study was to describe and compare the most frequent dermatologic adverse events with the use of biologic anti-TNF therapy in patients with RA in a real-life ambulatory setting.

Methods A descriptive study was done. A review of dermatological adverse event reports presented in pharmacovigilance committee was completed monthly during last 12 months in a specialized in RA center in Colombia. Descriptive epidemiology was used, percentages and averages were calculated.

Results 357 patients were using biological therapy in a cohort of 1678 RA patients last 12 months. Were 314 women (87.9%) and 43 (12.1%) men. Mean age 56.4 years old. In 31 (8.7% of all) patients were reported dermatologic adverse events (AE); AE were categorized according WHO classification in mild, moderate and severe; between them 14 (45.2%) were mild, 17 (54.8%) were moderate and none were severe. From 31 events reported, only 7 (22.6%) were biopsied and the other 24 cases were not clarified what type of dermatologic reaction presented (77.4%). For time of presentation, in first 15 days were informed 8 AE (25.8%), between 15 to 30 days were 6 (19.4%) AE, and more than 30 days were reported 17 (54.8%) AE. Regarding therapeutic approach in 5 patients (16.1%) biologic was temporarily suspended, in 14 (45.2%) was permanently withdrawn and patients were switched to another biological, and 12 (38.7%) patients were followed for drug and reactions surveillance. Concerning to type of biologic in 29 patients (93.5%), dermatologic adverse events were with anti-TNF therapies.

Conclusions Dermatological adverse events using biologics founded in patients of a specialized RA center are similar to those reported in literature; Biological therapy is considered a safe and recommended treatment for management of RA. Dermatologic AE were more mostly common with anti-TNFs therapies.

Disclosure of Interest None Declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.